A Pseftogas
The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGFβ Signaling
Pseftogas, A; Xanthopoulos, K; Poutahidis, T; Ainali, C; Dafou, D; Panteris, E; Kern, JG; Varelas, X; Hardas, A; Gonidas, C; Tsingotjidou, A; Hatzivassiliou, E; Mosialos, G
Authors
K Xanthopoulos
T Poutahidis
C Ainali
D Dafou
E Panteris
JG Kern
X Varelas
A Hardas
C Gonidas
A Tsingotjidou
E Hatzivassiliou
G Mosialos
Abstract
Downregulation of the cylindromatosis (CYLD) tumor suppressor has been associated with breast cancer development and progression. Here, we report a critical role for CYLD in maintaining the phenotype of mammary epithelial cells in vitro and in vivo. CYLD downregulation or inactivation induced an epithelial to mesenchymal transition of mammary epithelial cells that was dependent on the concomitant activation of the transcription factors Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) and transforming growth factor beta (TGF�)signaling. CYLD inactivation enhanced the nuclear localization of YAP/TAZ and the phosphorylation of Small Mothers Against Decapentaplegic (SMAD)2/3 proteins in confluent cell culture conditions. Consistent with these findings were the hyperplastic alterations of CYLD-deficient mouse mammary epithelia, which were associated with enhanced nuclear expression of the YAP/TAZ transcription factors. Furthermore, in human breast cancer samples, downregulation of CYLD expression correlates with enhanced YAP/TAZ-regulated target gene expression. Our results identify CYLD as a critical regulator of a signaling node that prevents the coordinated activation of YAP/TAZ and the TGF� pathway in mammary epithelial cells, in order to maintain their phenotypic identity and homeostasis. Consequently, they provide a novel conceptual framework that supports and explains a causal implication of deficient CYLD expression in aggressive human breast cancers.
Citation
Pseftogas, A., Xanthopoulos, K., Poutahidis, T., Ainali, C., Dafou, D., Panteris, E., Kern, J., Varelas, X., Hardas, A., Gonidas, C., Tsingotjidou, A., Hatzivassiliou, E., & Mosialos, G. (2020). The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGFβ Signaling. Cancers, 12(8), 2047. https://doi.org/10.3390/cancers12082047
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 13, 2020 |
Publication Date | Jul 24, 2020 |
Deposit Date | Aug 14, 2020 |
Publicly Available Date | Aug 14, 2020 |
Journal | Cancers |
Electronic ISSN | 2072-6694 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 12 |
Issue | 8 |
Pages | 2047 |
DOI | https://doi.org/10.3390/cancers12082047 |
Public URL | https://rvc-repository.worktribe.com/output/1376639 |
Publisher URL | https://doi.org/10.3390/cancers12082047 |
Files
12888_The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP_TAZ and TGFβ Signaling_GOLD VoR.pdf
(12.6 Mb)
PDF
You might also like
Downloadable Citations
About RVC Repository
Administrator e-mail: publicationsrepos@rvc.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search